Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Compugen ( (CGEN) ) has provided an announcement.
On March 4, 2025, Compugen Ltd. reported its financial results for the fourth quarter and full year 2024. The company highlighted significant progress in its clinical programs, including the development of COM701 and GS-0321, and its partnership with AstraZeneca on rilvegostomig. Compugen’s strong financial position, with a cash runway into 2027, supports its ongoing research and development efforts. The company aims to initiate a trial for COM701 in Q2 2025 and anticipates potential revenue from its partnerships.
More about Compugen
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapies. Utilizing its predictive computational discovery platform, Unigen, Compugen identifies new drug targets and biological pathways. The company has proprietary product candidates in development, including COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors. Compugen collaborates with partners like AstraZeneca and Gilead to advance its pipeline.
YTD Price Performance: 16.36%
Average Trading Volume: 731,979
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $171.9M
For detailed information about CGEN stock, go to TipRanks’ Stock Analysis page.